Magnolia Medical Technologies
Partnering with you to achieve near-zero blood culture contamination rates with Steripath
Seattle, United States
106 employees
Private Equity
Total: $117.33M
Health Care, Medical Devices
General Information
Get notified when Magnolia Medical Technologies moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Magnolia Medical Technologies
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Health Care
About Magnolia Medical Technologies
Taxonomy: Medical Device, Diagnostic Testing, Patient Safety, Sepsis Prevention, Infectious Disease Prevention, Blood Culture Collection, Antimicrobial Stewardship, Medical Reimbursement, Intellectual Property, Clinical Practice Improvement, Seattle, Innovation, Evidence-based Technology
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Private Equity Round | •••••• | 6 |
|
16 Feb 2022 |
| Debt Financing | •••••• | 1 |
|
27 May 2020 |
| Series C | •••••• | 4 |
|
30 Jan 2019 |
| Series B | •••••• | 1 |
|
04 Apr 2017 |
| Series B | •••••• | 1 |
|
15 Jul 2016 |
Magnolia Medical Technologies Alternatives & Competitors
Precision medicine for a sustainable world.
Rapid detection of sepsis-causing pathogens
AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of...
FAQ About Magnolia Medical Technologies
Don't just browse. Track.
Signal Tracker monitors Magnolia Medical Technologies and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
